Baseline comorbidities in a population-based cohort of rheumatoid arthritis receiving biological therapy: Data from the Australian Rheumatology Association database
Aims. To describe the baseline characteristics of an Australian population-based cohort of rheumatoid arthritis (RA) patients commencing biological therapy. Methods. Descriptive analysis from the Australian Rheumatology Association Database (ARAD). Results. Up to October 2006, there were 681 RA pati...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Hindawi Publishing Company
2009
|
| Online Access: | http://hdl.handle.net/20.500.11937/39887 |
| _version_ | 1848755716630773760 |
|---|---|
| author | Briggs, Andrew March, L. Lassere, M. Reid, C. Henderson, L. Murphy, B. van den Haak, R. Rischin, A. Staples, M. Buchbinder, R. |
| author_facet | Briggs, Andrew March, L. Lassere, M. Reid, C. Henderson, L. Murphy, B. van den Haak, R. Rischin, A. Staples, M. Buchbinder, R. |
| author_sort | Briggs, Andrew |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Aims. To describe the baseline characteristics of an Australian population-based cohort of rheumatoid arthritis (RA) patients commencing biological therapy. Methods. Descriptive analysis from the Australian Rheumatology Association Database (ARAD). Results. Up to October 2006, there were 681 RA patients taking biologics enrolled in ARAD. Baseline data were available for 624 (72% female, mean (SD) age 57.0 (12.5) years). Of these, 59.5% reported at least one comorbid condition, most commonly hypertension (35.7%) and osteoporosis (30.4%); 61 (9.8%) had a history of malignancy (35 nonmelanoma skin, 5 breast, 4 bowel, 5 cervix, 3 melanoma, 3 prostate and 1 each of lip, lung, myeloma, testis, uterus, vagina). Self-reported infections within the previous 6 months were common (71.5%). Conclusions. History of comorbidities, including recent infections, is common among Australian RA patients commencing biologics, and 10% have a history of malignancy. This may impact future evaluations of health outcomes among this population, including attribution of adverse events of biologic therapy. |
| first_indexed | 2025-11-14T09:00:44Z |
| format | Journal Article |
| id | curtin-20.500.11937-39887 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T09:00:44Z |
| publishDate | 2009 |
| publisher | Hindawi Publishing Company |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-398872017-09-13T15:05:59Z Baseline comorbidities in a population-based cohort of rheumatoid arthritis receiving biological therapy: Data from the Australian Rheumatology Association database Briggs, Andrew March, L. Lassere, M. Reid, C. Henderson, L. Murphy, B. van den Haak, R. Rischin, A. Staples, M. Buchbinder, R. Aims. To describe the baseline characteristics of an Australian population-based cohort of rheumatoid arthritis (RA) patients commencing biological therapy. Methods. Descriptive analysis from the Australian Rheumatology Association Database (ARAD). Results. Up to October 2006, there were 681 RA patients taking biologics enrolled in ARAD. Baseline data were available for 624 (72% female, mean (SD) age 57.0 (12.5) years). Of these, 59.5% reported at least one comorbid condition, most commonly hypertension (35.7%) and osteoporosis (30.4%); 61 (9.8%) had a history of malignancy (35 nonmelanoma skin, 5 breast, 4 bowel, 5 cervix, 3 melanoma, 3 prostate and 1 each of lip, lung, myeloma, testis, uterus, vagina). Self-reported infections within the previous 6 months were common (71.5%). Conclusions. History of comorbidities, including recent infections, is common among Australian RA patients commencing biologics, and 10% have a history of malignancy. This may impact future evaluations of health outcomes among this population, including attribution of adverse events of biologic therapy. 2009 Journal Article http://hdl.handle.net/20.500.11937/39887 10.1155/2009/861481 Hindawi Publishing Company fulltext |
| spellingShingle | Briggs, Andrew March, L. Lassere, M. Reid, C. Henderson, L. Murphy, B. van den Haak, R. Rischin, A. Staples, M. Buchbinder, R. Baseline comorbidities in a population-based cohort of rheumatoid arthritis receiving biological therapy: Data from the Australian Rheumatology Association database |
| title | Baseline comorbidities in a population-based cohort of rheumatoid arthritis receiving biological therapy: Data from the Australian Rheumatology Association database |
| title_full | Baseline comorbidities in a population-based cohort of rheumatoid arthritis receiving biological therapy: Data from the Australian Rheumatology Association database |
| title_fullStr | Baseline comorbidities in a population-based cohort of rheumatoid arthritis receiving biological therapy: Data from the Australian Rheumatology Association database |
| title_full_unstemmed | Baseline comorbidities in a population-based cohort of rheumatoid arthritis receiving biological therapy: Data from the Australian Rheumatology Association database |
| title_short | Baseline comorbidities in a population-based cohort of rheumatoid arthritis receiving biological therapy: Data from the Australian Rheumatology Association database |
| title_sort | baseline comorbidities in a population-based cohort of rheumatoid arthritis receiving biological therapy: data from the australian rheumatology association database |
| url | http://hdl.handle.net/20.500.11937/39887 |